Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 15/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15395713 | 1.00 | DOT1L (0.60) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15389514 | 1.00 | DOT1L (0.60) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9940664 | 0.95 | DOT1L (0.62) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9942287 | 0.93 | DOT1L (0.60) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9940452 | 0.93 | DOT1L (0.68) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15395748 | 0.93 | DOT1L (0.68) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9970643 | 0.91 | DOT1L (0.60) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9936593 | 0.90 | DOT1L (0.59) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9970739 | 0.90 | DOT1L (0.59) | DOT1LPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9940740 | 0.89 | DOT1L (0.64) | DOT1LPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |